Peritoneal dialysis (PD) and haemodialysis (HD) are life-saving renal replacement therapies for patients with chronic kidney disease.
PD is a cost-effective RRT, which performed at home can give the patient high quality of life. A point of care diagnostic to detect PD peritonitis would make this possible.
Renal replacement therapy is required for 5 million patients with chronic kidney therapy globally.
Peritoneal dialysis (PD) and haemodialysis (HD) are life-saving renal replacement therapies for patients with chronic kidney disease. Most receive hemodialysis, even though peritoneal dialysis is safer for patients and at least 2.3 times cheaper.
A major reason is the absence of a point of care diagnostic to detect PD peritonitis.
Using our patented VIPER technology, Detact Diagnostics® is developing RenoTact©.
Peritonitis is a common complication of peritoneal dialysis and may be directly related to peritoneal dialysis or secondary to a non-dialysis-related intra-abdominal or systemic process.
The vast majority of peritonitis cases are caused by bacteria. Identification of the bacteria as soon as possible is important to confirm or rule out a possible peritonitis, which is important in the treatment of peritonitis. In case of bacterial presence, antibiotic treatment can start immediately. Especially when peritoneal dialysis is performed at home or during weekends and after office hours, there can be delay in the diagnosis and treatment of a peritonitis.
The knowledge whether it’s a gram-positive or gram-negative bacteria can give the clinician useful information because PD-related peritonitis are mostly gram-positive bacteria and secondary peritonitis, more gram-negative bacteria.
There can be delay in the diagnosis of a peritonitis. Mainly because of gram stain and culture are time consuming. Methods to speed up this process can be very useful in clinical practice.
Chronic kidney disease (CKD) is a worldwide public health problem
Global RRT market is $1.8 billion/year, with a CAGR of 7.4% during 2020-2025.
Worldwide use of renal replacement therapie is projected to more than double to 5.439 million people by 2030.
Current estimates suggest that more than 500,000 patients receive peritoneal dialysis by 2027, representing approximately 11% of the dialysis population.
Detact Diagnostics® are developing RenoTact©, a test that can be done at home or at the general practitioner, providing actionable data in a few minutes and allowing immediate-early treatment of peritonitis with the goal of keeping a patient on PD longer before resorting to the more expensive and less safe HD.